Retinal and Optic Nerve Lesions Correspond to Amyloid in Autosomal Dominant Alzheimer's Disease

Amir H Kashani, M.D.^{1*}, Ph.D., Maya Koronyo-Hamaoui, Ph.D.^{2,3}, Yosef Koronyo, M.S.², Haoshen Shi², M.D., Ph.D.², Muhammed Alluwimi, O.D., Ph.D.¹, Maxwell Singer M.D.⁴, Abhay Sagare, Ph.D.⁵, Debra Hawes, M.D⁶., Anna Tang B.S.¹, Xuejuan Jiang Ph.D.⁴, Ana Collazo Martinez B.S.¹, Fred N. Ross-Cisneros Ph.D.⁷, Alfredo A. Sadun, M.D., Ph.D.^{7,8}, John M. Ringman, M.D., M.S^{9*}

*These authors contributed equally to this work.

Abstract

Autosomal dominant Alzheimer's disease (ADAD) is a rare form of Alzheimer's disease (AD) in which the biology of the disease can be explored during the presymptomatic phase of the illness. The retina is an outgrowth of the central nervous system and therefore provides the opportunity for direct observation of neural tissue and its vasculature during life. Retinal thinning measured *in vivo* has been previously described in persons carrying ADAD mutations through fundoscopy but its pathologic correlates have not been reported.

We describe retinal lesions detected using fundoscopy *in vivo* in a patient homozygous for the A431E mutation in *PSEN1* and its pathological correlates. Retinal lesions seen with fundoscopy during life corresponded to intraretinal and prelaminar optic nerve head amyloid β_{42} -protein that were surrounded by perivascular anti-11A50-B10- A β_{40} and gliosis. We then performed a cross-sectional, observational study of forty-one Latinos in three cohorts consisting of (1) persons with ADAD causing mutations, (2) at 50% risk for, but testing negative for ADAD mutations, and (3) elderly subjects not at-risk for ADAD.

Clinical exam demonstrated novel, yellow, intraretinal lesions in Cohort 1 in absence of drusen. Fifty-six percent of Cohort 1 subjects had >10 retinal lesions compared to 0% and 25% for Cohorts 2 and 3, respectively (P < 0.04). There has been some controversy as to the detectability of A β in the retina of persons with AD during life and our findings verify the presence of intraretinal, prelaminar, and perivascular amyloidosis detectable during life in a subset of AD patients.

Author affiliations:

- 1 Wilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland, 21287, USA
- 2 Department of Neurosurgery, Maxine Dunitz Neurosurgical Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
- 3 Departments of Neurology and Biomedical Sciences, Division of Applied Cell Biology and Physiology, Cedars-Sinai Medical Center, Los Angeles, CA, 90048 USA.

4 Keck School of Medicine at USC, Roski Eye Institute, Los Angeles, California, 90033, USA

5 Zilkha Neurogenetics Institute, University of Southern California, Los Angeles, CA, 90033 USA

- 6 Children's Hospital of Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, CA, 90027 USA
- 7 Doheny Eye Institute, Pasadena, California, 91103 USA

8 Department of Ophthalmology, David Geffen School of Medicine, University of California, Los Angeles, 90095 USA

9 Department of Neurology, Alzheimer's Disease Research Center, Department of Neurology, Keck School of Medicine at USC, Los Angeles, CA, 90033 USA

Correspondence to: Amir H Kashani MD PhD

Professor of Ophthalmology and Biomedical Engineering

Boone Pickens Professor of Ophthalmology

Wilmer Eye Institute, Johns Hopkins School of Medicine

600 N Wolfe St, Baltimore, MD 21287, USA

Email: akashan1@jhmi.edu

Telephone: 410-502-5052

John M. Ringman, M.D., M.S.

Helene and Lou Galen Professor of Clinical Neurology

Department of Neurology, Keck School of Medicine at USC

1520 San Pablo Street, Suite 3000

Email: John.Ringman@med.usc.edu

Running title: Retinal Amyloid in ADAD

Keywords: Latino, Presenilin, Fundus, Optical Coherence Tomography

Introduction

Alzheimer's Disease (AD) is characterized by extracellular deposition of $A\beta$ in the brain parenchyma as plaques, and within the walls of small cerebral vessels as cerebral amyloid angiopathy (CAA).¹ Also present are abnormal intraneuronal cytoskeletal structures containing hyperphosphorylated tau protein as neurofibrillary tangles (NFTs). Histopathological studies of the eyes of patients have demonstrated a reduction in the number of retinal ganglion cells, reduced thickness of the retinal nerve fiber layer and reduction of axonal profiles in the optic nerve of subjects with mild cognitive impairment (MCI) due to AD as well as persons with AD dementia.²⁻⁹ Thinning of various retinal layers has also been demonstrated in vivo in numerous human clinical studies.^{7,10-11} Other in vivo studies in humans have shown either impaired arteriolar vessel reactivity, reduced foveal avascular zone size, or decreased blood flow in the superficial macula in late onset Alzheimer's disease (LOAD).¹²⁻¹⁴ Histopathological analyses of the human retina in LOAD have demonstrated the microscopic presence of tau-related changes¹⁵⁻¹⁸ as well as beta-amyloid (Aβ) plaques and vascular A β deposits.^{1,5-7,17-22} Although histopathological findings and accompanying *in vivo* retinal amyloid imaging reports have demonstrated promising insights, ^{5-9,15-43} the clinical identification of AD-specific retinal pathology remains challenging. This difficulty arises from the high prevalence of comorbid retinal conditions such as drusen or hard exudates (e.g. age-related macular degeneration, diabetic retinopathy, etc.) which are indistinguishable from potential AD-related changes during routine clinical examinations in the elderly population.

Unlike the common form of AD (LOAD), around 1% of AD cases are due to fully penetrant genetic mutations that are inherited in an autosomal dominant manner and termed autosomal

dominant AD (ADAD).⁴⁴ For subjects that carry an ADAD mutation, development of clinical AD is essentially certain, with the age of symptom onset being relatively young (typically < 60 years of age) and fairly predictable based on the specific mutation present.⁴⁵ Though the clinical and pathological phenotypes of ADAD are generally similar to those of LOAD, there are some differences⁴⁶ including a higher prevalence of CAA in ADAD.⁴⁷ Since ADAD occurs much earlier than LOAD, ADAD subjects serve as a useful model for identifying AD biomarkers by minimizing the influence of confounders that are associated with aging such as age-related macular degeneration, vascular disease and hypertension. As such, characterization of retinal changes in persons with ADAD mutations is a valuable model for understanding the disease course and utility of ocular biomarkers in a "pure" form of AD. Initial studies in ADAD cohorts have found marginally decreased thickness of several retinal layers in presymptomatic *PSEN1* mutation (E280A) carriers¹⁰ as well as carriers of other mutations⁴⁸ and corresponding attenuation of optic tract projections.³¹ Histological analysis of postmortem retinas from ADAD patients, heterozygous carriers of the PSEN1 A260V or A431E mutations, revealed elevated $A\beta_{42}$ and $A\beta$ -oligomer levels, comparable to those observed in the retinas of LOAD patients.⁶ Abnormally elevated and heterogeneous retinal capillary blood flow patterns have also been demonstrated in presymptomatic carriers of PSEN1 and APP mutations.⁴⁹

Here, we report the first clinical and postmortem histopathological characterization of intraretinal findings in a patient who was homozygous for a pathogenic *PSEN1* (A431E substitution)⁵⁰⁻⁵² mutation. We correlate these dilated fundus examination findings with clinical findings on fundus photos, optical coherence tomography (OCT), and OCT angiography (OCTA), and demonstrate that the retinal abnormalities seen *in vivo* correlate spatially with areas of positive intraretinal A β staining seen post-mortem. We also report the clinical and ophthalmological findings from a larger cohort of persons with ADAD mutations relative to a cohort of non-mutation carrying controls and a cohort of elderly persons with various levels of cognitive impairment.

Materials and methods

Subject Recruitment

This was a cross-sectional study containing three cohorts of Latino subjects recruited in an ongoing NIH funded observational study (R01AG062007) from 2017 to 2022. Cohort 1 consisted of consecutive subjects with genetic mutations known to cause ADAD. Cohort 2 subjects were at-risk members of families in whom ADAD mutations were known to occur but who were themselves not found to be mutation carriers on genetic testing. Cohort 3 subjects were elderly Latino subjects (>50 years old) with various degrees of cognitive impairment. All participants underwent standardized clinical and cognitive evaluations using the Uniform Data Set 3 (UDS3) of the Alzheimer's Disease Center network⁵³ and participants in Cohort 3 underwent amyloid-PET scans using florbetaben to evaluate for the presence of cerebral amyloidosis.

Ophthalmologic Examination

All subjects underwent a comprehensive ophthalmologic examination including assessment of standardized Early Treatment of Diabetic Retinopathy Severity (ETDRS) visual acuity, intra-ocular pressure, slit-lamp examination and dilated funduscopic examination by a boardcertified ophthalmologist and fellowship-trained retina specialist.

Ophthalmic Imaging

Ophthalmic imaging was performed on both eyes of all subjects after pharmacologic pupil dilation. Cooperation of some symptomatic subjects was limited due to dementia. Color fundus photographs were obtained from up to seven ETDRS fields with a 30-50° true-color fundus camera (TRC 50DX, Topcon, Livermore, CA) and evaluation of the retinal periphery and macula was also performed with pseudocolored wide-field scanning laser fundus camera (Optomap, Optos, Marlborough, MA, USA). Images were reviewed for quality and presence of lesions by trained graders masked to the underlying clinical condition and genotype. Grading was performed for the appearance of the neurosensory retina, retinal vessels, optic nerve, and ocular media as well as any abnormal retinal or choroidal lesions. Fundus photographs which were not of sufficient quality for assessment of lesions were discarded but

all images from all recruited subjects were evaluated. Fundus photographs that were partially useful due to vignetting or other media opacity were evaluated for lesions only in the usable portion of the image.

Optical coherence tomography (OCT) images of the central macula (6x6mm) were acquired using a Heidelberg Spectralis (Spectralis, Heidelberg Engineering, Franklin, MA, USA). Retinal thickness and sublayer thickness (nerve fiber layer, ganglion cell layer, inner plexiform layer, inner nuclear layer, outer plexiform layer, outer nuclear layer and outer retinal banding pattern) for each eye were quantified using the commercially available segmentation and measurement software (Spectralis, Heidelberg Engineering, Franklin, MA, USA).

Optical coherence tomography angiograms (OCTA) of the central macula (3x3mm) were obtained using an AngioPlex 5000 (Carl Zeiss Meditec, Dublin, CA, USA). OCTA were automatically segmented by the manufacturer's commercially available software to construct *en face* superficial retinal layer (SRL) images. The SRL extends from the inner limiting membrane (ILM) through the inner plexiform layer (IPL), which is approximated as 70% of the thickness between the ILM and outer plexiform layer (OPL). This segmentation methodology is commercially available and has been described before.⁵⁴ All images were assessed for quality including signal strength index (provided by manufacturer software), motion artifact, media opacity and foveal centration.

Quantitative Capillary Perfusion and Density Measures

Quantitation of OCTA images for capillary density and morphology in the SRL was performed as described previously⁵⁴⁻⁵⁶ with modifications to exclude the foveal avascular zone (FAZ) and non-capillary vessels such as arterioles and venules. Capillary density was measured as vessel skeleton density (VSD) which represents the total length of capillaries. VSD is calculated by reducing the width of binarized vessels to one pixel and then dividing those skeletonized vessel pixels by the total dimensions of the image excluding areas occupied by non-capillary vessels. Capillary blood flow was measured as capillary flux (cF), which is calculated by averaging the nonbinarized decorrelation intensity values of the pixels

occupied by capillaries.⁵⁷⁻⁵⁸ This approximates capillary blood flow because the raw decorrelation intensity values for capillaries in an OCTA image are correlated with the number of erythrocytes passing through a capillary segment per unit time.⁵⁸ Capillary density and flux for the autopsied subject were compared against a set of previously published⁴⁹ subjects at risk for ADAD.^{19,21,23-28,49}

Ocular Histopathology

Processing of eye tissue, retinal flat mounts and cross-sections, and optic

nerve

The donor eyes with the optic nerves were collected within 8 hours after time of death and were punctured and fixed in 10% neutral buffered formalin (NBF) and stored at 4°C. The fixed eyes were dissected to create eyecups. The complete neurosensory retinas were isolated, detached from the choroid and sclera, flat mounts prepared, and the vitreous humor thoroughly removed manually, as previously described.⁵⁻⁶ The flat mount retina topographical quadrants (superior, temporal, inferior, nasal) were defined by identifying the macula, optic disc, and blood vessels. Flat mount strips (~2mm wide) were prepared from four predefined geometric subregions: superior-temporal (ST), inferior-temporal (IT), inferior-nasal (IN), and superior-nasal (SN) retina, spanning diagonally from the optic disc to the ora serrata. Fixed retinal strips were processed for cross-sectioning. Each strip measured approximately 2.5cm from the optic disc to the ora serrata, and the central (C), mid-(M), and far (F) peripheral subregions were further defined based on their radial distance from the optic disc. The flat mount temporal quadrant was separated for immunohistochemistry. This tissue preparation technique allowed for extensive and consistent access to retinal quadrants, layers, and pathological subregions.

Paraffin-embedded retinal cross-sections

Flat mount-derived strips were initially paraffinized using the standard techniques. Next, strips were embedded in paraffin after flip-rotating 90° horizontally. The retinal strips were sectioned (7-10µm thick) and placed on microscope slides treated with 3-aminopropyltriethoxysilane (APES, Sigma A3648). Before immunohistochemistry, the

sections were deparaffinized with 100% xylene twice (10 min each), rehydrated with decreasing concentrations of ethanol (100% to 70%), and washed with distilled water followed by PBS.

Immunohistochemistry

The flat mount temporal quadrant and the deparaffinized retinal cross-sections (tissues) were washed with 1xPBS and treated with target retrieval solution (pH 6.1; S1699, DAKO) at 99°C for 1 hour and washed with 1xPBS. The retinal cross-sections were then treated with formic acid 70% (ACROS) for 10 minutes at room temperature (RT) and washed with PBS before staining for A β and pTau burden. For peroxidase-based immunostaining, tissues were washed with wash buffer (Dako S3006) and added 0.2% Triton X-100 (Sigma, T8787) for 1 hour and then treated with 3% H₂O₂ for 20 minutes at room temperature and rinsed with wash buffer.

Retinal flat mount temporal quadrant was incubated with mouse anti-human $A\beta_{42}$ monoclonal antibody (12F4 clone; react to the C-terminus of A β and specific to $A\beta_{42}$ isoforms; 1:500; Biolegend, Cat.# 805501), for 48 hrs at 4°C. The primary antibody was diluted in the Ab diluent solution with background-reducing components (DAKO S3022). Retinal crosssections were incubated with 12F4 mAb (1:500) or with rabbit anti-Tau(pSer396) pAb (AS-54977; 1:2000), diluted with background-reducing components, for overnight at 4°C. Tissues were rinsed thrice (10 min each) with wash buffer on a shaker, and incubated for 45 minutes at 37°C with secondary antibodies (anti-mouse Ab, HRP conjugated, DAKO Envision K4001 or anti-rabbit Ab, HRP conjugated, DAKO Envision K4003), and rinsed thrice with wash buffer. For all tissues, 3,3-diaminobenzidine (DAB) substrate was used (DAKO K3468). For retinal cross-sections that were stained with $A\beta_{42}$ mAb, hematoxylin counterstaining was performed. All tissues were mounted with Paramount aqueous mounting medium (Dako, S3025).

For fluorescence-based immunostaining, retinal cross-sections were treated with blocking solution (DAKO X0909) supplemented with 0.1% Triton X-100 (Sigma, T8787), then washed with 1xPBS prior to overnight incubation at 4°C with the following primary

antibodies: mouse anti-human $A\beta_{42}$ mAb (12F4 clone, 1:200; Biolegend, Cat.# 805501), mouse anti-human $A\beta_{40}$ mAb (11A50-B10 clone; react to the C-terminus of A β and specific to $A\beta_{40}$ isoforms; 1:200; Biolegend, Cat.# 805401), rat anti-GFAP mAb (1:500; Invitrogen, Cat. # 13-0300), rabbit anti-collagen IV pAb (1:500; Abcam, Cat. # ab6586); goat anti-IBA1 pAb (1:500; Novusbio, Cat.# NB100-1028). The following day, retinal cross-sections were washed thrice with 1xPBS and incubated with secondary antibodies (1:200; Donkey antimouse, -rat, -rabbit or -goat, Cy5, Cy3 and Cy2, Jackson Immunoresearch laboratories, INC.), for 1 hour at room temperature. After rinsing thrice with 1xPBS, sections were mounted with Prolong Gold antifade reagent with DAPI (Thermo Fisher #P36935). Routine controls were processed using identical protocol while omitting the primary antibodies to assess nonspecific labeling.

Microscopy

Bright field and fluorescence images were acquired using a Carl Zeiss Axio Imager Z1 fluorescence microscope with ZEN 2.6 blue edition software (Carl Zeiss MicroImaging, Inc.) equipped with ApoTome, and AxioCam MRm and AxioCam HRc cameras. Multi-channel image acquisition was used to create images with multiple channels. Tiling mode and post-acquisition stitching were used to capture and analyze large areas. Images were repeatedly captured at the same focal planes with the same exposure time. Images were captured at $20\times$, $40\times$, $63\times$, and $100\times$ objectives for different purposes.

Group Comparisons

In order to ascertain whether detectable retinal abnormalities associated with ADAD mutation status were present during life in persons with ADAD mutations, fundus photographs from all cohorts were reviewed by a grader masked to the participants' genetic status and clinical exam findings. The images were graded to determine the presence, number, and location of abnormal retinal lesions within or around the retina, optic nerve head and retinal vessels. These lesion counts were tabulated in relation to disease stage as determined by the Clinical Dementia Rating scale (CDR), presence vs. absence of the pathogenic ADAD mutations, retinal location and age-adjusted for mutation-specific age of dementia diagnosis. As age of disease onset differs more between mutations than within a mutation,⁴⁵ a mutation-specific adjusted-age of diagnosis can be calculated as an estimation

of the time remaining from the expected age at which dementia will develop. Comparisons were made between groups using non-parametric Kolmogorov-Smirnov tests and Chisquared tests where appropriate using R version 4.2.3 (R Foundation for Statistical Computing; Vienna, Austria).

Data availability

Data from this manuscript are available for review based on written requests for noncommercial use, with appropriate IRB approval and legitimate research goals. Since retinal images are considered inherently identifiable and there are very few subjects with or at risk for ADAD some images may not be sharable to protect subject privacy.

Results

Study Population

Of the 25 subjects at risk for ADAD, *PSEN1* and *APP* mutations were found in 15 and three subjects, respectively (Table 1). Among 18 mutation carriers, five were asymptomatic (CDR = 0), three were mildly symptomatic (CDR = 0.5) and 10 had dementia (CDR > 0.5). Among the 18 mutation carriers, two had the F388S substitution in *PSEN1*,⁶⁰ three had the V717I substitution in *APP*,⁶¹ and 13 had the A431E *PSEN1* substitution.⁵¹⁻⁵² Cohort 3 consisted of 16 Latinos of whom six had grossly normal cognition, four had mild cognitive impairment, and six had dementia. All six with dementia had positive amyloid-PET scans and were considered to have AD. One person with normal cognition had a positive amyloid-PET scan.

As the *APOE* epsilon 2 and 4 alleles have been found to be associated with CAA,⁶² we assessed these genotypes as well. One out of seven (14%) non-carriers (Cohort 2), and 5/18 (28%) carriers in Cohort 1 had an *APOE* 2 or 4 allele. Of these five carriers, one (20.0%) was an asymptomatic carrier, one (20.0%) was a mildly symptomatic carrier and three (60%) had dementia. Three subjects in Cohort 3 were homozygotes for these alleles and five were of the 3/4 genotype.

Pre-mortem and post-mortem evaluation of homozygote for A431E substitution in PSEN1

During the course of this study, one subject in Cohort 1 (henceforth called the index subject) passed away from secondary complications of ADAD approximately 20.5 months after his last study examination. Ocular and CNS tissue from this subject was available for histopathologic evaluation as described below. This subject was homozygous for the A431E substitution in PSEN1. He began declining in cognition, motor function, and passed away all in his 30s (exact ages have been redacted due to publication guidelines). His overall clinical presentation excluding ocular findings has been previously described.⁶³ While he had family history of ADAD, the exact details are redacted due to publication guidelines to protect patient privacy. At the time of ophthalmologic examination he had significant leg spasticity (Ashworth score of 3/4 in both legs), was unable to walk independently, and was hyperflexic throughout with bilateral Babinski signs. He had advanced dementia with a CDR score of 3 (severe dementia) and a sum of boxes score of 18 (maximal disability). He scored 8/30 on the MMSE and the severity of his dementia precluded more formal neuropsychological testing. He had an earlier onset and more aggressive course of the disease than typically seen in association with his mutation. This subject underwent histopathologic evaluation and, while his ophthalmologic findings were consistent with findings in Cohort 1, they were not included in Table 1 due to his inability to perform some clinical ophthalmological testing.

Neuropathological Evaluation of homozygote for A431E substitution in PSEN1

The post-mortem interval for brain and ocular tissue collection for the index subject was 8 hours. Mild atrophy was evident in the frontal and temporal lobes with moderately severe atrophy appreciable in the hippocampus. Hematoxylin and eosin staining revealed granulovacuolar degeneration, neuronal loss and a few Hirano bodies. The entorhinal cortex also demonstrated neuronal loss and granulovacuolar degeneration. The neocortices (frontal, temporal, parietal) all demonstrated neuronal loss. Anti- β amyloid immunostain 4G8 revealed frequent, diffuse plaques in the hippocampus, frontal, temporal, parietal, occipital lobes, basal ganglia, pons and midbrain. A moderate amount of plaques were also identified in the

cerebellum. Grade I amyloid angiopathy was identified in the hippocampus CA1, entorhinal cortex and in the neocortices (frontal, temporal, parietal and occipital lobes). Gallyas silver stain revealed frequent neuritic plaques, neurofibrillary tangles and neuropil threads in the CA1 region of the hippocampus, entorhinal cortex, frontal, temporal, parietal and occipital cortices. The midbrain showed no Lewy bodies, neuronal loss or gliosis though it did demonstrate pigmentary incontinence. With anti-alpha-synuclein immunostain, there were also no Lewy bodies present in the substantia nigra, locus coeruleus or medulla. The ADNC grading was A3, B3, C3, representing a high probability of Alzheimer's Disease. The Braak score was VI.

Ophthalmological Evaluation of the homozygote for A431E substitution in PSEN1

The index patient was unable to cooperate with visual acuity testing due to his advanced dementia. His smooth pursuit eye movements had saccadic intrusions; the full assessment of extraocular motility was limited as he was unable to reliably follow commands. The intraocular pressures were within normal limits for both eyes. The slit-lamp examination of the anterior segment was unremarkable. Dilated funduscopic examination demonstrated multiple, small to very fine, yellow deposits that appeared to be most prominent in the neurosensory retina of both maculae and range in size from 20-100 microns as noted in other subjects in Cohort 1 (Fig. 1). Color fundus photographs from the index subject demonstrated some of the retinal lesions that had been observed clinically although many were not resolved or remained slightly out of focus due to motion artifacts and the subject's limited ability to position (Fig. 2). Color images of the optic disc demonstrated moderate perivascular whitening.

OCT scans of macular thickness in the index subject demonstrated normal foveal contour and no clear intraretinal or subretinal lesions in any section (Fig. 2). Specifically, no retinal drusen were noted on any OCT section in any subject in Cohort 1. We compared the total retinal thickness and sublayer thickness of the index subject to corresponding published mean retinal measurements from subjects carrying other ADAD causing mutations and controls.^{10,48-49} Total retinal thickness as well as all sublayer thicknesses (retinal nerve fiber

layer, ganglion cell layer, inner plexiform layer and outer nuclear layer) for the index subject were well below published values from subjects with similar mutations and controls consistent with the advanced stage of the index subject's disease (Table 2). OCTA of each eye did not demonstrate qualitatively obvious focal areas of capillary loss (Supplemental Fig. 1A,B). However, capillary perfusion was both qualitatively and quantitatively lower (Supplemental Fig. 1D). Both capillary blood flow and capillary density metrics for the index subject were more than one standard deviation below the mean of a group of 33 eyes from 17 normal subjects (Supplemental Fig. 1E,F). The average age of this group of normal subjects used for comparison was 37.8 ± 10.3 .

Elevated A β_{42} , pTau, vascular A β_{40} , and gliosis in ADAD retina

Both donor eyes were harvested from the index subject approximately 20.5 months after his last clinical evaluation. Immunohistochemistry of retinal flat mounts from the left eye using anti-A β_{42} monoclonal antibody and previously described methods²⁰ demonstrated diffusely and densely positive staining in regions of the retina that had been noted before to have clinically visible retinal lesions. Using retinal vessels as landmarks, focal areas of increased immunostaining were noted and corresponded to clinically visible retinal lesions on fundus images and examination (Fig. 3).

Retinal flat mounts were cut and cross-sectioned from the superior-temporal and inferior temporal regions were prepared as described in the methods section to evaluate the presence of AD-related pathology, including A β and pTau reactivity within the retinal layers (Fig. 4). Retinal cross-sections throughout the superotemporal region of the left eye demonstrated diffuse and dense anti-Tau (pSer396) immunoreactivity that was most prominent in the inner plexiform layer and less prominent in the outer nuclear layer (Fig. 4A-B). Numerous cell bodies in the inner nuclear layer and surrounding inner blood vessels were exhibiting intense pS396-tau inclusions as well (Fig. 4C-G). There was diffuse reactivity throughout the retinal cross-section for anti-A β_{42} and this was most prominent in the nerve fiber layer and especially in regions surrounding blood vessels (Fig. 4H-J). Immunofluorescence for A β_{42} (12F4), along with vascular collagen IV and GFAP-positive astroglia showed the presence of A β_{42} deposits within the retinal nerve fiber layer and within the walls of larger retinal vessels confirming the presence of retinal vascular amyloidosis (Fig. 5A-B). Moreover, dense

vascular A β_{40} (11A50-B10) signals within collagen IV-positive vessel walls and multiple activated IBA-1-positive microglia were observed in the retina of this ADAD patient (Fig. 5C).

Histopathology of optic nerve from the index homozygote for

A431E substitution in PSEN1

 $A\beta_{42}$ was found in the prelaminar (anterior) optic nerve head (Fig. 6). In contradistinction, there was a paucity of $A\beta_{42}$ within the lamina cribosa and almost no $A\beta_{42}$ in the post-laminar optic nerve head where the axons are myelinated. (Fig. 6A-C) The anteriorly located $A\beta_{42}$ appeared in aggregates and sometimes in the vicinity of a few identifiable plaques (Fig. 6D-E). There was also a dense accumulation of $A\beta_{42}$ around the blood vessels of the optic nerve head (Fig. 6C) which corresponded to perivascular whitening on fundus photographs (Fig. 2D). In the retina adjacent to the optic disc, both nasally and temporally, there was very little $A\beta_{42}$.

Retinal lesions on dilated fundus examination across cohorts

Fundus examinations and imaging were available for all 82 eyes from 41 subjects in all cohorts. Comorbid health conditions among the relatively young subjects in Cohort 1 (subjects with mutation predisposing to ADAD) and Cohort 2 (family members with no mutation predisposing to ADAD) were less prevalent compared to the elderly subjects in Cohort 3. Table 1 summarizes the subject demographics. Dilated fundus examination of Cohort 1 subjects demonstrated yellow, mostly circular, retinal lesions of varying sizes that were atypical for the relatively young age and low burden of comorbid disease in this cohort (Fig. 1). Among all subjects in Cohort 1, there were 348 lesions with a median (\pm IQR) of 11 \pm 13 lesions per subject. Among all non-mutation carrying relatives of ADAD subjects (i.e. Cohort 2 subjects), there were 38 lesions with a median (\pm IQR) of 7 \pm 7 lesions per subject. Among all elderly subjects in Cohort 3, there were 185 lesions with a median (\pm IQR) of 4 \pm 8.5 lesions per subject. The number of retinal lesions in Cohort 1 to Cohort 3 the number of total retinal lesions was approaching statistical significance (D = 0.40, P = 0.08). Using the median number of lesions in Cohort 1 (10 lesions) as a threshold for comparison of the three

cohorts, there were no subjects in Cohort 2 that had more than 10 lesions and only 4/16 (25%) subjects in Cohort 3 with more than 10 lesions. In contrast, 10/18 carriers (56%) in Cohort 1 had more than 10 lesions (Chi-squared = 7.8939, P = 0.02), supporting the observation that these findings are related to the presence of ADAD mutations.

Among subjects with ADAD causing mutations (Cohort 1), there were 115 (33%), 98 (28%), 103 (30%), and 32 (9%) lesions in the superotemporal, inferotemporal, inferonasal and superonasal quadrants, respectively. Among the non-ADAD mutation carriers in Cohort 2, there were 18 (47.4%), 10 (26.3%), 3 (7.9%), and 7 (18.4%) lesions in similar regions, respectively. Among elderly subjects (Cohort 3), there were 72 (38.9%), 46 (24.8%), 26 (14.1%), and 41 (22.2%) lesions in similar regions, respectively. Seven subjects (39%) in Cohort 1 and four subjects (22%) in Cohort 3 had lesions 2 disc diameters (DD) or closer from the optic nerve head (ONH), while all lesions in Cohort 2 were 3 DD or further from the ONH (Chi-squared = 3.9274, P = 0.1403). In terms of size, 89% and 80% of lesions were between ~1-30 microns in ADAD and controls (Cohort 3), respectively (D = 0.385, P = 0.06). In a few cases from Cohort 1 and Cohort 3, lesions were irregularly shaped and were greater than 400 microns. There was no direct relationship with the number of retinal lesions and either participants' adjusted-age nor with disease status as indexed by the CDR sum of boxes.

Discussion

We describe the clinical examination and diagnostic imaging findings, consistent with intraretinal amyloid lesions, in a cohort of relatively healthy young subjects with mutations predisposing to ADAD. Many of these lesions were perivascular in distribution. Unlike older subjects, these subjects were all below the age of 60 and had fewer comorbid conditions that would predispose to retinal lesions such as drusen, hard exudates or other retinal pigment epithelial pathology. We show the frequency of retinal lesions is higher in subjects with ADAD predisposing mutations when compared to controls at-risk but not carrying such mutations. A similar but insignificant trend is noted when comparing with elderly subjects with cognitive impairment due to other causes. To support the association of intraretinal lesions observed on clinical examination with underlying ADAD pathology, we also show histopathology from the retina and optic nerve head of an index patient from this cohort who

was homozygous for the A431E mutation in *PSEN1*. To our knowledge, this is the first paper to report the dilated fundus examination findings, including fundus photos, coregistered with histopathology of intraretinal and pre-laminar disc amyloid deposition. Notably, no subject with an ADAD mutation had drusen on macular OCT scans, including the index subject who had macular lesions. Therefore, we do not believe these lesions are retinal drusen. Previous studies have reported a sluggish pupil flash response among pre-symptomatic carriers of an E693Q amyloid precursor protein (*APP*) mutation.⁶⁴ This is consistent with the findings that melanopsin retinal ganglion cells (mRGCs), which subserve the afferent limb of the pupillary response, are early targets of A β pathology in AD.⁷ *APP* mutations, like *PSEN1* mutations, are ADAD causing mutations with the E693Q *APP* mutation causing disproportionate CAA.

The lesions we report on dilated fundus examination and in fundus photos in the index subject were associated with areas found on histopathological analysis to have $A\beta$ deposition within the retina (Fig. 4) and optic disc (Fig. 6). Beyond detection of A β plaques in flat mounts, we observed the accumulation of $A\beta_{42}$ and vascular $A\beta_{40}$ deposits, pS396-tau isoforms, and IBA1⁺ micro-and GFAP⁺ macro-gliosis in retinal cross sections from this ADAD patient (Fig. 4-Fig. 6). These retinal pathological changes are consistent with those previously described in LOAD patients.^{5-9,15-23,27-43} Notably, the index patient was already quite symptomatic at the time of his eye examination. As pathological abnormalities associated with AD may occur decades before onset of dementia, an important goal of research into AD pathology in the retina is to develop early biomarkers for AD before the more obvious clinical onset of symptoms. Because the index patient was already symptomatic, it is unclear at what point the retinal lesions would have clinically manifested in this patient. It is also possible that these lesions change, evolve or even resolve with time. Regardless, in this study we provide evidence that the AD hallmark pathology is present in the retina and is amenable to routine color fundus imaging. More specialized forms of retinal imaging may have additional benefits in detecting these lesions.^{5,20,65}

Masked assessment of retinal images from 25 persons known to harbor ADAD mutations confirmed that the retinal lesions are ~1.6 times more abundant among carriers than in a cohort of subjects at risk for inheriting ADAD mutations (family members without mutations), and ~2.8 times more abundant than in an unrelated cohort of subjects with

cognitive impairment and a median age more than 20 years older. Though sometimes present in early disease (e.g. one carrier of the A431E *PSEN1* mutation with a CDR score of 0.5 had 46 lesions), they were not ubiquitous, even in persons with more advanced dementia. The participant with the most lesions (97, affected by the V717I *APP* mutation) had a CDR score of 2.0 and the single patient with a CDR score of 3 (also with the A431E *PSEN1* mutation) had only 11 lesions identified. The longevity of these lesions is also not known and it is possible that they turn over with time. There is substantial heterogeneity in the clinical and neuropathological features between ADAD mutations,⁴⁶ with some having atypical amyloid plaque composition and morphology^{60,66} or having variable predisposition to CAA,⁴⁷ so the relationship between cerebral and ophthalmological A β deposition may vary with the mutation.

Many of the retinal lesions we noted appeared to be perivascular or near blood vessels in distribution so it is possible that their appearance in the retina is subject to the same factors determining the presence of CAA. Indeed, both the A431E and F388S mutations in PSEN1 are associated with a high prevalence of CAA (and atypical "cotton wool" amyloid plaques)^{47,60} and intraretinal lesions may be more likely to occur in these cases. Measures of retinal capillary perfusion in the index subject were consistent with previous descriptions from our group and others.^{14,49,67} Specifically, retinal capillary perfusion was decreased as measured by OCTA compared to a set of previously published subjects at risk for ADAD. Previous studies have also reported that retinal AB plaques can be associated with blood vessels⁵ and other studies have demonstrated retinal vascular changes in AD.¹²⁻¹⁴ We have previously reported *increased* retinal capillary perfusion in presymptomatic ADAD mutation carriers and decreased perfusion in late-stage disease.⁴⁹ These data are consistent with there being an initial phase of hyperemia associated with early inflammation or compensatory blood flow that declines as the disease advances.⁶⁸⁻⁶⁹ The clinical appearance of retinal lesions may reflect an underlying imbalance in amyloid deposition and clearance related to retinal perfusion changes. Our findings provide more evidence that retinal vascular measurements from OCTA should be evaluated as a potential biomarker for AD.

The study of persons with ADAD allows us to more accurately define changes specific to the AD process and are less subject to influence by the aging process itself or its co-morbidities

such as retinal drusen (associated with age related macular degeneration), hard exudates (associated with retinal vascular diseases such as diabetes retinopathy or hypertension) or other retinal lesions. As such, the generalizability of these findings to the characterization of LOAD is unknown as the co-morbidities of aging are associated with confounding non-specific changes in the retina. Methods seeking to label retinal lesions as amyloid in humans *in vivo* are being developed^{5,19,23-28} and, if successful, could change the way AD is currently diagnosed and managed.

An important consideration in this study is the disproportionate number of carriers of the *APOE* epsilon 2 or 4 alleles among ADAD carriers with dementia. As these genetic variants are known to increase the risk of CAA, and therefore possibly of amyloid detectable in the retina, this could have confounded our results. Though the mean number of lesions among carriers of the *APOE* epsilon 2 or 4 alleles, regardless of ADAD mutation status, was numerically higher (15.73 vs. 12.88, P = 0.68) this was not statistically significant nor were there significant differences in the number of carriers of *APOE* epsilon 2 or 4 allele carriers that had more than 10 lesions relative to non-carriers of these variants (47% vs. 35%, P = 0.67. Further study with larger numbers of participants will be necessary to determine if there are independent or combined contributions of ADAD mutation and *APOE* genotype to these retinal lesions or CAA. Defining the nature and prevalence of these retinal lesions across the AD spectrum will require larger studies employing a wide range of participants with diverse subtypes of the disease.

In conclusion, we show definitive evidence that deposits of $A\beta$ in the retina and optic nerve head can be detected *in vivo* with fundoscopy or clinically available fundus imaging in a homozygote for the A431E mutation in *PSEN1*. Our evidence in a wider population of living persons with ADAD mutations suggests this is a significant feature of this disease and may be an early biomarker of disease burden. The degree and manner to which these findings can be applied to the larger population at-risk for AD remains to be determined and will require further study.

Acknowledgements

The authors would like to acknowledge Drs. Carol Miller and Debra Hawes for the neuropathological evaluation of the subject. Dr. Amir Kashani performed or supervised the acquisition and analysis of all ophthalmologic data. Dr. John Ringman performed or supervised the acquisition and analysis of all clinical neurological data. Dr. Maya Koronyo performed or supervised the postmortem analysis of the retina. Dr. Alfredo Sadun performed or supervised the postmortem analysis of the optic disc. Dr. Xuejuan Jiang supervised the statistical analyses. The authors would also like to thank Ms. Anna Tang for help with preparation and submission of the manuscript.

Funding

AHK and JMR are supported by R01EY030564, U01AG051218, UH3NS100614, and R01AG062007. MKH and YK are supported by the National Institutes of Health (NIH)/National Institute on Aging (NIA) grants: R01AG056478, R01AG075998, and R01AG055865, as well as supported by The Hertz Innovation Fund, and the Gordon, Jona Goldrich, and Haim Saban Private Foundations.

Competing interests

AHK is a consultant and recipient of research funding/materials from Carl Zeiss Meditec and consultant to Regenxbio, Aspen Biosciences and Alcon. JMR is a DMC member of Renew Group Private Limited and a consultant for InnoSense. YK and MKH are co-founding members and minor shareholders of NeuroVision Imaging Inc. The other authors report no competing interests.

Supplementary material

Supplementary material is available online.

References

- Kashani A, Koronyo-Hamaou M, Sadun A. Retinal Manifestations of Neurodegeneration: A Focus on Alzheimer's Disease. In: Sadda S, ed. *Ryan's Retina; Seventh Edition*. Seventh Edition ed. Elsevier; 2023:696-708:chap 31.
- Asanad S, Ross-Cisneros FN, Barron E, et al. The retinal choroid as an oculovascular biomarker for Alzheimer's dementia: A histopathological study in severe disease. *Alzheimers Dement (Amst)*. Dec 2019;11:775-783. https://doi.org/10.1016/j.dadm.2019.08.005
- Blanks JC, Hinton Dr Fau Sadun AA, Sadun Aa Fau Miller CA, Miller CA. Retinal ganglion cell degeneration in Alzheimer's disease. (0006-8993 (Print))
- Hinton DR, Sadun AA, Blanks JC, Miller CA. Optic-nerve degeneration in Alzheimer's disease. *N Engl J Med.* Aug 21 1986;315(8):485-7. https://doi.org/10.1056/NEJM198608213150804
- Koronyo Y, Biggs D, Barron E, et al. Retinal amyloid pathology and proof-of-concept imaging trial in Alzheimer's disease. *JCI Insight*. Aug 2017;2(16). https://doi.org/10.1172/jci.insight.93621
- Koronyo Y, Rentsendorj A, Mirzaei N, et al. Retinal pathological features and proteome signatures of Alzheimer's disease. *Acta Neuropathol*. Apr 2023;145(4):409-438. https://doi.org/10.1007/s00401-023-02548-2
- La Morgia C, Ross-Cisneros FN, Koronyo Y, et al. Melanopsin retinal ganglion cell loss in Alzheimer disease. *Ann Neurol.* Jan 2016;79(1):90-109. https://doi.org/10.1002/ana.24548
- 8. Gaire BP, Koronyo Y, Fuchs DT, et al. Alzheimer's disease pathophysiology in the Retina. Prog Retin Eye Res. 2024;101:101273. doi:10.1016/j.preteyeres.2024.101273
- Davis MR, Robinson E, Koronyo Y, et al. Retinal ganglion cell vulnerability to pathogenic tau in Alzheimer's disease. Preprint. bioRxiv. 2024;2024.09.17.613293. Published 2024 Sep 21. doi:10.1101/2024.09.17.613293
- Armstrong GW, Kim LA, Vingopoulos F, et al. Retinal Imaging Findings in Carriers With PSEN1-Associated Early-Onset Familial Alzheimer Disease Before Onset of Cognitive Symptoms. (2168-6173 (Electronic))
- Chan VTT, Sun Z, Tang S, et al. Spectral-Domain OCT Measurements in Alzheimer's Disease: A Systematic Review and Meta-analysis. (1549-4713 (Electronic))

- Lahme L, Esser EL, Mihailovic N, et al. Evaluation of Ocular Perfusion in Alzheimer's Disease Using Optical Coherence Tomography Angiography. (1875-8908 (Electronic))
- 13. O'Bryhim BE, Apte RS, Kung N, Coble D, Van Stavern GP. Association of Preclinical Alzheimer Disease With Optical Coherence Tomographic Angiography Findings. (2168-6173 (Electronic))
- Querques G, Borrelli EA-O, Sacconi RA-O, et al. Functional and morphological changes of the retinal vessels in Alzheimer's disease and mild cognitive impairment. (2045-2322 (Electronic))
- 15. den Haan JA-O, Morrema THJ, Verbraak FD, et al. Amyloid-beta and phosphorylated tau in post-mortem Alzheimer's disease retinas. (2051-5960 (Electronic))
- 16. Du X, Koronyo Y, Mirzaei N, et al. Label-free hyperspectral imaging and deeplearning prediction of retinal amyloid β-protein and phosphorylated tau. *PNAS Nexus*. Sep 2022;1(4):pgac164. https://doi.org/10.1093/pnasnexus/pgac164
- 17. Hart de Ruyter FJ, Morrema THJ, den Haan J, et al. Phosphorylated tau in the retina correlates with tau pathology in the brain in Alzheimer's disease and primary tauopathies. *Acta Neuropathol*. Feb 2023;145(2):197-218. https://doi.org/10.1007/s00401-022-02525-1
- Walkiewicz G, Ronisz A, Van Ginderdeuren R, et al. Primary retinal tauopathy: A tauopathy with a distinct molecular pattern. *Alzheimers Dement*. Jan 2024;20(1):330-340. https://doi.org/10.1002/alz.13424
- Cao KJ, Kim JH, Kroeger H, et al. ARCAM-1 Facilitates Fluorescence Detection of Amyloid-Containing Deposits in the Retina. *Transl Vis Sci Technol.* Jun 01 2021;10(7):5. https://doi.org/10.1167/tvst.10.7.5
- 20. Koronyo-Hamaoui M, Koronyo Y, Ljubimov AV, et al. Identification of amyloid plaques in retinas from Alzheimer's patients and noninvasive in vivo optical imaging of retinal plaques in a mouse model. *Neuroimage*. Jan 2011;54 Suppl 1:S204-17. https://doi.org/10.1016/j.neuroimage.2010.06.020
- 21. Schultz N, Byman E, Wennström M, Bank NB. Levels of Retinal Amyloid-β Correlate with Levels of Retinal IAPP and Hippocampal Amyloid-β in Neuropathologically Evaluated Individuals. *J Alzheimers Dis*. 2020;73(3):1201-1209. https://doi.org/10.3233/JAD-190868

- 22. Shi H, Koronyo Y, Rentsendorj A, et al. Identification of early pericyte loss and vascular amyloidosis in Alzheimer's disease retina. *Acta Neuropathol*. May 2020;139(5):813-836. https://doi.org/10.1007/s00401-020-02134-w
- Dumitrascu OM, Lyden PD, Torbati T, et al. Sectoral segmentation of retinal amyloid imaging in subjects with cognitive decline. *Alzheimers Dement (Amst)*.
 2020;12(1):e12109. https://doi.org/10.1002/dad2.12109
- 24. Hadoux X, Hui F, Lim JKH, et al. Non-invasive in vivo hyperspectral imaging of the retina for potential biomarker use in Alzheimer's disease. *Nat Commun.* 09 2019;10(1):4227. https://doi.org/10.1038/s41467-019-12242-1
- 25. Lemmens S, Van Craenendonck T, Van Eijgen J, et al. Combination of snapshot hyperspectral retinal imaging and optical coherence tomography to identify Alzheimer's disease patients. *Alzheimers Res Ther*. Nov 10 2020;12(1):144. https://doi.org/10.1186/s13195-020-00715-1
- 26. More SS, Beach JM, McClelland C, Mokhtarzadeh A, Vince R. In Vivo Assessment of Retinal Biomarkers by Hyperspectral Imaging: Early Detection of Alzheimer's Disease. ACS Chem Neurosci. 11 2019;10(11):4492-4501. https://doi.org/10.1021/acschemneuro.9b00331
- 27. Ngolab J, Donohue M, Belsha A, et al. Feasibility study for detection of retinal amyloid in clinical trials: The Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) trial. *Alzheimers Dement (Amst)*. 2021;13(1):e12199. https://doi.org/10.1002/dad2.12199
- 28. Tadokoro K, Yamashita T, Kimura S, et al. Retinal Amyloid Imaging for Screening Alzheimer's Disease. J Alzheimers Dis. 2021;83(2):927-934. https://doi.org/10.3233/JAD-210327
- 29. Du X, Park J, Zhao R, et al. Hyperspectral retinal imaging in Alzheimer's disease and age-related macular degeneration: a review. Acta Neuropathol Commun.
 2024;12(1):157. Published 2024 Oct 3. doi:10.1186/s40478-024-01868-y
- 30. Shi H, Mirzaei N, Koronyo Y, et al. Identification of retinal oligomeric, citrullinated, and other tau isoforms in early and advanced AD and relations to disease status. Acta Neuropathol. 2024;148(1):3. Published 2024 Jul 9. doi:10.1007/s00401-024-02760-8
- Dumitrascu OM, Doustar J, Fuchs DT, et al. Distinctive retinal peri-arteriolar versus peri-venular amyloid plaque distribution correlates with the cognitive performance. Preprint. bioRxiv. 2024;2024.02.27.580733. Published 2024 Feb 29. doi:10.1101/2024.02.27.580733

- 32. Shi H, Koronyo Y, Fuchs DT, et al. Retinal arterial Aβ40 deposition is linked with tight junction loss and cerebral amyloid angiopathy in MCI and AD patients. Alzheimers Dement. 2023;19(11):5185-5197. doi:10.1002/alz.13086
- 33. Dumitrascu OM, Rosenberry R, Sherman DS, et al. Retinal Venular Tortuosity Jointly with Retinal Amyloid Burden Correlates with Verbal Memory Loss: A Pilot Study. Cells. 2021;10(11):2926. Published 2021 Oct 28. doi:10.3390/cells10112926
- 34. Shi H, Koronyo Y, Rentsendorj A, et al. Retinal Vasculopathy in Alzheimer's Disease. Front Neurosci. 2021;15:731614. Published 2021 Sep 22. doi:10.3389/fnins.2021.731614
- 35. Doustar J, Torbati T, Black KL, Koronyo Y, Koronyo-Hamaoui M. Optical Coherence Tomography in Alzheimer's Disease and Other Neurodegenerative Diseases. Front Neurol. 2017;8:701. Published 2017 Dec 19. doi:10.3389/fneur.2017.00701
- 36. Hart NJ, Koronyo Y, Black KL, Koronyo-Hamaoui M. Ocular indicators of Alzheimer's: exploring disease in the retina. Acta Neuropathol. 2016;132(6):767-787. doi:10.1007/s00401-016-1613-6
- 37. Grimaldi A, Pediconi N, Oieni F, et al. Neuroinflammatory Processes, A1 Astrocyte Activation and Protein Aggregation in the Retina of Alzheimer's Disease Patients, Possible Biomarkers for Early Diagnosis. Front Neurosci. 2019;13:925. Published 2019 Sep 4. doi:10.3389/fnins.2019.00925
- 38. Lee S, Jiang K, McIlmoyle B, et al. Amyloid Beta Immunoreactivity in the Retinal Ganglion Cell Layer of the Alzheimer's Eye. Front Neurosci. 2020;14:758. Published 2020 Jul 31. doi:10.3389/fnins.2020.00758
- 39. Qiu Y, Jin T, Mason E, Campbell MCW. Predicting Thioflavin Fluorescence of Retinal Amyloid Deposits Associated With Alzheimer's Disease from Their Polarimetric Properties. Transl Vis Sci Technol. 2020;9(2):47. Published 2020 Aug 14. doi:10.1167/tvst.9.2.47
- Xu QA, Boerkoel P, Hirsch-Reinshagen V, et al. Müller cell degeneration and microglial dysfunction in the Alzheimer's retina. Acta Neuropathol Commun. 2022;10(1):145. Published 2022 Oct 5. doi:10.1186/s40478-022-01448-y
- 41. Nuñez-Diaz C, Andersson E, Schultz N, et al. The fluorescent ligand bTVBT2 reveals increased p-tau uptake by retinal microglia in Alzheimer's disease patients and AppNL-F/NL-F mice. Alzheimers Res Ther. 2024;16(1):4. Published 2024 Jan 2. doi:10.1186/s13195-023-01375-7

- 42. Hart de Ruyter FJ, Evers MJAP, Morrema THJ, et al. Neuropathological hallmarks in the post-mortem retina of neurodegenerative diseases. Acta Neuropathol. 2024;148(1):24. Published 2024 Aug 19. doi:10.1007/s00401-024-02769-z
- 43. Cao Q, Yang S, Wang X, et al. Transport of β-amyloid from brain to eye causes retinal degeneration in Alzheimer's disease. J Exp Med. 2024;221(11):e20240386. doi:10.1084/jem.20240386
- Goate AM. Molecular genetics of Alzheimer's disease. Research Support, U.S. Gov't, P.H.S.Review. *Geriatrics*. Sep 1997;52 Suppl 2:S9-12.
- 45. Ryman DC, Acosta-Baena N, Aisen PS, et al. Symptom onset in autosomal dominant Alzheimer disease: A systematic review and meta-analysis. *Neurology*. Jul 15 2014;83(3):253-60. https://doi.org/10.1212/WNL.00000000000596
- 46. Ringman JM, Goate A, Masters CL, et al. Genetic heterogeneity in Alzheimer disease and implications for treatment strategies. *Curr Neurol Neurosci Rep.* Nov 2014;14(11):499. https://doi.org/10.1007/s11910-014-0499-8
- 47. Ringman JM, Monsell S, Ng DW, et al. Neuropathology of Autosomal Dominant Alzheimer Disease in the National Alzheimer Coordinating Center Database. J Neuropathol Exp Neurol. Mar 2016;75(3):284-90. https://doi.org/10.1093/jnen/nlv028
- 48. Adhikari S, Qiao Y, Singer M, et al. Retinotopic degeneration of the retina and optic tracts in autosomal dominant Alzheimer's disease. *Alzheimers Dement*. Apr 27, 2023. https://doi.org/10.1002/alz.13100
- 49. Singer MB, Ringman JM, Chu Z, et al. Abnormal retinal capillary blood flow in autosomal dominant Alzheimer's disease. (2352-8729 (Print))
- 50. Dumois-Petersen S, Gallegos-Arreola MP, Magaña-Torres MT, Perea-Díaz FJ, Ringman JM, Figuera LA-O. Autosomal dominant early onset Alzheimer's disease in the Mexican state of Jalisco: High frequency of the mutation PSEN1 c.1292C>A and phenotypic profile of patients. (1552-4876 (Electronic))
- 51. Murrell J, Ghetti B, Cochran E, et al. The A431E mutation in PSEN1 causing familial Alzheimer's disease originating in Jalisco State, Mexico: an additional fifteen families. *Neurogenetics*. Nov 2006;7(4):277-9. https://doi.org/10.1007/s10048-006-0053-1
- 52. Yescas P, Huertas-Vazquez A, Villarreal-Molina MT, et al. Founder effect for the Ala431Glu mutation of the presenilin 1 gene causing early-onset Alzheimer's disease

> in Mexican families. *Neurogenetics*. Jul 2006;7(3):195-200. https://doi.org/10.1007/s10048-006-0043-3

- 53. Besser L, Kukull W, Knopman DS, et al. Version 3 of the National Alzheimer's Coordinating Center's Uniform Data Set. *Alzheimer Dis Assoc Disord*. 2018;32(4):351-358. doi:10.1097/WAD.00000000000279
- 54. Kim AY, Chu Z, Shahidzadeh A, Wang RK, Puliafito CA, Kashani AH. Quantifying Microvascular Density and Morphology in Diabetic Retinopathy Using Spectral-Domain Optical Coherence Tomography Angiography. (1552-5783 (Electronic))
- 55. Chu Z, Lin J, Gao C, et al. Quantitative assessment of the retinal microvasculature using optical coherence tomography angiography. (1560-2281 (Electronic))
- 56. Reif R, Qin J, An L, Zhi Z, Dziennis S, Wang R. Quantifying optical microangiography images obtained from a spectral domain optical coherence tomography system. (1687-4196 (Electronic))
- 57. Abdolahi F, Zhou X, Ashimatey BS, et al. Optical Coherence Tomography Angiography-Derived Flux As a Measure of Physiological Changes in Retinal Capillary Blood Flow. *Transl Vis Sci Technol.* 08 02 2021;10(9):5. https://doi.org/10.1167/tvst.10.9.5
- 58. Kushner-Lenhoff S, Li Y, Zhang Q, Wang RK, Jiang X, Kashani AH. OCTA Derived Vessel Skeleton Density Versus Flux and Their Associations With Systemic Determinants of Health. *Invest Ophthalmol Vis Sci*. Feb 01 2022;63(2):19. https://doi.org/10.1167/iovs.63.2.19
- 59. Wang RK, Zhang Q, Li Y, Song S. Optical coherence tomography angiography-based capillary velocimetry. *J Biomed Opt.* 06 2017;22(6):66008. https://doi.org/10.1117/1.JBO.22.6.066008
- 60. Ringman JM, Dorrani N, Fernández SG, et al. Characterization of spastic paraplegia in a family with a novel. *Brain Commun.* 2023;5(2):fcad030. https://doi.org/10.1093/braincomms/fcad030
- 61. Goate A, Chartier-Harlin MC, Mullan M, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. *Nature*. Feb 21 1991;349(6311):704-6. https://doi.org/10.1038/349704a0
- 62. Hostettler IC, Seiffge D, Wong A, et al. and Cerebral Small Vessel Disease Markers in Patients With Intracerebral Hemorrhage. *Neurology*. Sep 20 2022;99(12):e1290e1298. https://doi.org/10.1212/WNL.000000000200851

- 63. Parker J, Mozaffar T, Messmore A, Deignan JL, Kimonis VE, Ringman JM. Homozygosity for the A431E mutation in PSEN1 presenting with a relatively aggressive phenotype. *Neurosci Lett.* Apr 23 2019;699:195-198. https://doi.org/10.1016/j.neulet.2019.01.047
- 64. Frost SM, Kanagasingam Y, Sohrabi HR, et al. Pupil response biomarkers distinguish amyloid precursor protein mutation carriers from non-carriers. *Curr Alzheimer Res*. Oct 2013;10(8):790-6.
- 65. Kashani AH, Asanad S, Chen J, et al. Past, present and future role of retinal imaging in neurodegenerative disease. *Prog Retin Eye Res.* Jan 2021:100938. https://doi.org/10.1016/j.preteyeres.2020.100938
- 66. Crook R, Verkkoniemi A, Perez-Tur J, et al. A variant of Alzheimer's disease with spastic paraparesis and unusual plaques due to deletion of exon 9 of presenilin 1. *Nat Med.* Apr 1998;4(4):452-5. https://doi.org/10.1038/nm0498-452
- 67. O'Bryhim BE, Apte RS, Kung N, Coble D, Van Stavern GP. Association of Preclinical Alzheimer Disease With Optical Coherence Tomographic Angiography Findings. *JAMA Ophthalmol.* 11 2018;136(11):1242-1248. https://doi.org/10.1001/jamaophthalmol.2018.3556
- 68. Asanad S, Ross-Cisneros FN, Nassisi M, Barron E, Karanjia R, Sadun AA. The Retina in Alzheimer's Disease: Histomorphometric Analysis of an Ophthalmologic Biomarker. *Invest Ophthalmol Vis Sci.* 04 2019;60(5):1491-1500. https://doi.org/10.1167/iovs.18-25966
- 69. Tsai Y, Lu B, Ljubimov AV, et al. Ocular changes in TgF344-AD rat model of Alzheimer's disease. *Invest Ophthalmol Vis Sci.* Jan 29 2014;55(1):523-34. https://doi.org/10.1167/iovs.13-12888

Figure legends

Figure 1 True color fundus photographs from 4 different representative subjects at risk for Autosomal Dominant Alzheimer's Disease (ADAD, Cohort 1). (A) Subject 1 is a 55-59 year old female with an APP V717I mutation, APOE 3/3 genotype, and adjusted-age of 2. There was no medical history of diabetes mellitus, hypertension or hypercholesterolemia. CDR-SOB score was 10. There were 97 lesions detected on all available fundus images for

this subject. In addition to the area of the white box, there were numerous fine lesions immediately nasal to the disc which may be difficult to resolve on the fundus photograph. (**B**) Subject 2, a 40-44 year old female with PS1 A431E mutation, APOE 2/3 genotype, and adjusted-age of 2. CDR-SOB score was 13. There were 66 lesions detected on all available fundus images for this subject. (**C**) Subject 3, a 45-49 year old male with PS1 A431E mutation, APOE 3/3 genotype, and adjusted-age of 0. CDR-SOB score was 7. There were 7 lesions detected on all available fundus images for this subject undus images for this subject. (**D**) Subject 4, a 55-59 year old female with no family history of dementia or risk for ADAD. Genotyping for this subject was not available. CDR-SOB score was 0. There were 4 lesions detected on all available fundus images for this subject. Exemplary lesions for all cases are illustrated in white box, inset and/or black arrows. True color images were acquired on a Topcon TRC 50DX.

Figure 2 Fundus photographs of an index 35-39 year old PSEN1 homozygote who passed away during the course of the study from complications associated with ADAD. Pseudocolor widefield fundus images of the posterior pole in the (A) right and (B) left eyes demonstrate subtle fine yellow lesions in the macula that were initially noted on clinical examination. Higher magnification images are provided in inset. White arrowheads indicate locations of some of the more prominent clinically visible lesions. An incidental choroidal nevus is noted in the superior macula. (C) True color fundus photograph of the right optic disc and (D) left optic disc demonstrate very mild perivascular whitening along the nasal artery. (E) Magnified true color fundus photograph of right macula taken on a true color fundus camera more clearly demonstrates fine refractile, yellow lesions in temporal macula. (F) Similar findings in magnified true color images of left macula. (G) Magnified region of white box from panel (E). (H) Magnified images from white dotted box from panel (F). Foveal OCT B-scans of the (I) right eye and (J) left eyes show unremarkable foveal depression and retinal contour. There were no drusen on any macular OCT scan noted in this subject. White arrows and arrowheads in all panels indicate location of exemplary and clinically notable lesions. Many more lesions were visible on clinical examination with 2.2 diopter and 66 diopter lenses than are apparent on fundus photographs due to subtle blurring from patient motion. Pseudocolored images were taken on an Optos 200Tx. True color images were acquired on a Topcon TRC 50DX. All images were acquired 20.5 months before death. Images have not been contrast altered or visually enhanced.

Figure 3 Histopathology of $A\beta_{42}$ deposition in flat mount of retinal regions and corresponding fundus images from an index subject with PSEN1 mutation. This is the same subject as illustrated in Fig. 2. (A) True color fundus photograph of subject's left eye. An incidental choroidal nevus is noted in the superior macula. Regions labelled 1-3 in white dotted boxes represent areas with exemplary clinically visible lesions although numerous other regions with fine lesions were also notable on clinical examination. The most easily evident of these lesions is in area 3. (B,C) Higher magnification of regions in panel A. White or black arrows highlight the location of lesions. Immunohistochemistry for $A\beta_{42}$, labelled by using the 12F4 monoclonal antibody, on retinal flat mounts from the numbered regions in the white dotted regions is provided in subsequent panels A1-A3. Additional image from the A3 flat mount region included several large $A\beta$ plaques. (A1) Region temporal to the fovea was noted to have numerous fine refractile, yellow lesions near a retinal vessel (red) coming in from the temporal region. Translucent sharp lines represent retinal blood vessels in flat mounts and provide orientation and landmarks.

Figure 4 Retinal A β_{42} and hyperphosphorylated tau (pSer396) immunoreactivity in cross-sections from a 35-39 year old ADAD patient homozygous for A431E mutation in **PSEN1** gene. Immunohistochemical analysis of $A\beta_{42}$ (12F4) and Tau(pSer396) immunoreactivity in retinal cross-sections from 35-39 year old index PSEN1 homozygote. Retinal cross-sections were prepared as described in the methods section. (A) Color fundus photograph of the left eye (OS). Yellow lines show the superior-temporal (ST) and inferior-temporal (IT) strips from which retinal cross-sections were prepared for immunostaining. (B-G) Anti-Tau(pSer396) immunoreactivity was visualized by peroxidasebased DAB labeling and noted most prominently in the inner plexiform layer and in numerous cell bodies located in the inner nuclear layer. (C) Dense retinal pTau signals surrounding inner blood vessels (black arrowheads) within the NF/GC layers. (D) Intracellular pTau accumulation within INL cells and along the IPL synapses and ganglion cell axons. (E-G) Higher magnification images showing NFT-like structures of dense pTau inclusions (red arrows) within INL cells. (H-J) Anti-A\beta_{42} immunostaining using the 12F4 mAb and visualized by peroxidase-based DAB labeling showed the presence of diffuse $A\beta_{42}$ deposits across all retinal layers and most densely in the retinal nerve fiber layer. More intense staining was noted around and within retinal vessel walls. Occasionally, intense A β_{42} staining is further found in the outer retina, in photoreceptors, above the outer limiting membrane, and in the IPL. Scale bars = $50 \,\mu\text{m}$, unless otherwise specified.

Figure 5 Retinal vascular amyloidosis and gliosis in 35-39 year old index PSEN1 homozygote. (A,B) Representative images of immunofluorescence staining for A β_{42} (12F4, red), GFAP astrocytes (green), vascular collagen IV (CollV, blue) and nuclei (DAPI, cyan) in retinal cross-sections from the index ADAD patient. Intense A β_{42} accumulation appears around and within inner blood vessels and the nerve fiber layer (NFL). (C) Representative images of immunofluorescence staining for vascular A β_{40} (11A50-B10, red), IBA1 microglia (green), vascular collagen IV (CollV, blue), and nuclei (DAPI, cyan) in retinal cross-sections. Intense A β_{40} deposition is detected within inner blood vessel walls. Scale bars = 20 µm.

Figure 6 Histopathology of $A\beta_{42}$ deposition in cross-sections of the optic nerve head from index subject with PSEN1 mutation. (A) Low magnification image of the optic nerve head shows positive $A\beta_{42}$ staining in the prelaminar space and near a few larger vessels. Higher magnification images demonstrating (B) essentially no staining at or posterior to the lamina cribrosa, (C-E) numerous areas of $A\beta_{42}$ staining in the prelaminar region and (F) modest $A\beta_{42}$ staining in the peripapillary retina.

Supplementary Figure 1 Full thickness, pseudocolored, *en face* and foveal centered OCTA scan (AngioPlex, Carl Zeiss Meditec, Inc) of a 35-39 year old PSEN1 homozygote. 3x3mm image of retinal capillary perfusion in the right (A) and left eye (B). Quantitation of capillary blood flow (E) and vessel skeleton density (F) as measured by OCTA of the index patient in red compared to normal subjects in grey with black bars corresponding to one standard deviation above and below the mean for a set of 33 eyes from 17 normal subjects (Singer et al., ADAD 2021). Note that for both measurements, the patient was more than one standard deviation below the mean.

Cohort 1 (ADAD mutation carrier) $N = 18$ Cohort 2 (ADAD mutation non- carrier) $N = 7$ Cohort 3 (at risk for MCI or dementia $N = 16$ Total Number of subjects, n PSEN1 A431E, n (%) PSEN1 F388S, n (%) APP V717I, n (%) PSEN1 F388S, n (%) APP V717I, n (%) Not available, n (%)18 2 (11.1%) 3 (16.7) 0 (0%)7 0 0 016 (100%)Total Number of eyes Right eyes, n (%) Left eyes, n (%)36 18 (50%) 18 (50%)14 7 (50%)32 16 (50%)Total Number of males, n (%)9 (50%) mit 9 (50%) mit3 (42.8%) mit 37 (22 - 44) mit5 (31%) mit 67 (53 - 89) mitMedian age (range)42 (23 - 57) mit 0 (-21 - 6)Not ApplicableNot Applicable	Table 1. Summary of subject characteristics and ophthalmic findings				
Total Number of subjects, n 18 7 16 $PSEN1 A431E, n (\%)$ 13 (72.2%) 0 0 $PSEN1 F388S, n (\%)$ 2 (11.1%) 0 0 $APP V717I, n (\%)$ 3 (16.7) 0 0 $PSEN1 G206A (\%)$ 0 (0%) 0 0 Not available, n (%) 0 (0%) 0 (0%) 16 (100%) Total Number of eyes 36 14 32 Right eyes, n (%) 18 (50%) 16 (50%) 16 (50%) Left eyes, n (%) 18 (50%) 7 (50%) 16 (50%) Number of males, n (%) 9 (50%) ⁿ⁵ 3 (42.8%) ⁿ⁵ 5 (31%) ⁿ⁵ Median age (range) 42 (23 - 57) ^{**} 37 (22 - 44) ^{**} 67 (53 - 89) ^{**}		Cohort 1 (ADAD mutation carrier) N = 18	Cohort 2 (ADAD mutation non- carrier) <i>N</i> = 7	Cohort 3 (at risk for MCI or dementia) N = 16	
PSEN1 A431E, $n (\%)$ 13 (72.2%) 0 PSEN1 F388S, $n (\%)$ 2 (11.1%) 0 APP V7171, $n (\%)$ 3 (16.7) 0 PSEN1 G206A (%) 0 (0%) 0 Not available, $n (\%)$ 0 (0%) 0 Total Number of eyes 36 14 32 Right eyes, $n (\%)$ 18 (50%) 7 (50%) 16 (50%) Left eyes, $n (\%)$ 18 (50%) 7 (50%) 16 (50%) Number of males, $n (\%)$ 9 (50%) ^{1%} 3 (42.8%) ^{1%} 5 (31%) ^{1%} Median age (range) 42 (23 - 57) ^{1*} 37 (22 - 44) ^{1*} 67 (53 - 89) ^{1*}	Total Number of subjects, n	18	7	16	
PSENI F 3885, $n (\%)$ 2 (11.1%) 0 APP V7171, $n (\%)$ 3 (16.7) 0 PSENI G 206A (%) 0 (0%) 0 Not available, $n (\%)$ 0 (0%) 0 (0%) Total Number of eyes 36 14 32 Right eyes, $n (\%)$ 18 (50%) 7 (50%) 16 (50%) Left eyes, $n (\%)$ 18 (50%) 7 (50%) 16 (50%) Number of males, $n (\%)$ 9 (50%) ^{1%} 3 (42.8%) ^{1%} 5 (31%) ^{1%} Median age (range) 42 (23 - 57) ^{1*} 37 (22 - 44) ^{1*} 67 (53 - 89) ^{1*}	PSEN1 A431E, n (%)	13 (72.2%)	0		
APP V717I, n (%) 3 (16.7) 0 PSEN1 G206A (%) 0 (0%) 0 Not available, n (%) 0 (0%) 0 (0%) Total Number of eyes 36 14 Right eyes, n (%) 18 (50%) 7 (50%) 16 (50%) Left eyes, n (%) 18 (50%) 7 (50%) 16 (50%) Number of males, n (%) 9 (50%) ^{ns} 3 (42.8%) ^{ns} 5 (31%) ^{ns} Median age (range) 42 (23 - 57) ^{ns} 37 (22 - 44) ^{ns} 67 (53 - 89) ^{ns}	PSEN1 F3885, n (%)	2 (11.1%)	0		
PSEN1 G 206A (%) Not available, n (%) 0 (0%) 0 (0%) 0 0 Total Number of eyes Right eyes, n (%) 36 14 32 Left eyes, n (%) 18 (50%) 7 (50%) 16 (50%) Left eyes, n (%) 18 (50%) 7 (50%) 16 (50%) Number of males, n (%) 9 (50%) ¹⁵ 3 (42.8%) ¹⁵ 5 (31%) ¹⁵ Median age (range) 42 (23 - 57) ¹⁴ 37 (22 - 44) ¹⁴ 67 (53 - 89) ¹⁷ Median Adjusted Age ¹ (range) 0 (-21 - 6) Not Applicable Not Applicable	APP V7171, n (%)	3 (16.7)	0		
Not available, n (%) 0 (0%) 0 (0%) 16 (100%) Total Number of eyes 36 14 32 Right eyes, n (%) 18 (50%) 7 (50%) 16 (50%) Left eyes, n (%) 18 (50%) 7 (50%) 16 (50%) Number of males, n (%) 9 (50%) ^{ns} 3 (42.8%) ^{ns} 5 (31%) ^{ns} Median age (range) 42 (23 - 57) ^T 37 (22 - 44) ^T 67 (53 - 89) ^T Median Adjusted Age ¹ (range) 0 (-21 - 6) Not Applicable Not Applicable	PSEN1 G 206A (%)	0 (0%)	0		
Total Number of eyes Right eyes, n (%) 36 14 32 Left eyes, n (%) 18 (50%) 7 (50%) 16 (50%) Left eyes, n (%) 18 (50%) 7 (50%) 16 (50%) Number of males, n (%) 9 (50%) ^{ns} 3 (42.8%) ^{ns} 5 (31%) ^{ns} Median age (range) 42 (23 - 57) ^{**} 37 (22 - 44) ^{**} 67 (53 - 89) ^{**} Median Adjusted Age ¹ (range) 0 (-21 - 6) Not Applicable Not Applicable	Not available, n (%)	0 (0%)	0 (0%)	16 (100%)	
Number of males, n (%) 18 (50%) 7 (50%) 16 (50%) Number of males, n (%) 9 (50%) ¹⁵ 3 (42.8%) ¹⁵ 5 (31%) ¹⁵ Median age (range) 42 (23 - 57) ¹¹ 37 (22 - 44) ¹¹ 67 (53 - 89) ¹¹ Median Adjusted Age ³ (range) 0 (-21 - 6) Not Applicable Not Applicable	Total Number of eves	36	14	32	
Inglice (s), n (%) 10 (50%) 10 (50%) Left eyes, n (%) 18 (50%) 7 (50%) Number of males, n (%) 9 (50%) ^{ns} 3 (42.8%) ^{ns} Median age (range) 42 (23 - 57) ^{ns} 37 (22 - 44) ^{ns} Median Adjusted Age ¹ (range) 0 (-21 - 6) Not Applicable	Right eves $n(\%)$	18 (50%)	7 (50%)	16 (50%)	
Number of males, n (%) 9 (50%) ^{ns} 3 (42.8%) ^{ns} 5 (31%) ^{ns} Median age (range) 42 (23 - 57) ^{rs} 37 (22 - 44) ^{rs} 67 (53 - 89) ^{rs} Median Adjusted Age ¹ (range) 0 (-21 - 6) Not Applicable Not Applicable	left eves n (%)	18 (50%)	7 (50%)	16 (50%)	
Median age (range) 42 (23 - 57) ^{**} 37 (22 - 44) ^{**} 67 (53 - 89) ^{**} Median Adjusted Age ¹ (range) 0 (-21 - 6) Not Applicable Not Applicable	Number of males n (%)	9 (50%) ^{ns}	$3(42.8\%)^{ns}$	5 (31%) ^{ns}	
Median age (range) 42 (23 - 57) 37 (22 - 44) 67 (53 - 89) Median Adjusted Age ¹ (range) 0 (-21 - 6) Not Applicable Not Applicable		5 (50%)	5 (+2.070)	3 (31/0)	
Median Adjusted Age ¹ (range) 0 (-21-6) Not Applicable Not Applicable	Median age (range)	42 (23 – 57)	37 (22 – 44)	67 (53 – 89)	
	Median Adjusted Age ¹ (range)	0 (-21-6)	Not Applicable	Not Applicable	
Comorbid Diagnoses	Comorbid Diagnoses				
Hypertension, n (%) 3 (16.7%) 0 (0%) 6 (37.5%)	Hypertension, n (%)	3 (16.7%)	0 (0%)	6 (37.5%)	
Diabetes Mellitus, n (%) 0 (0%) 0 (0%) 2 (13%)	Diabetes Mellitus, n (%)	0 (0%)	0 (0%)	2 (13%)	
Hyperlipidemia, n (%) 3 (16.7%) 0 (0%) 12 (75%)	Hyperlipidemia, n (%)	3 (16.7%)	0 (0%)	12 (75%)	
MCI, n (%) 2 (11.1%) 0 (0%) 4 (25%)	MCI, n (%)	2 (11.1%)	0 (0%)	4 (25%)	
Dementia, n (%) 11 (61.1%) 0 (0%) 6 (37.5%)	Dementia, n (%)	11 (61.1%)	0 (0%)	6 (37.5%)	
Other ^{2,3,4} , n (%) 15 (83%) 5 (71.4%) 15 (94%)	Other ^{2,3,4} , <i>n</i> (%)	15 (83%)	5 (71.4%)	15 (94%)	
APOE 2 or 4 genotype, n (%) 5 (27.8%) ^{ns} 1 (14.3%) ^{ns} 9 (56%) ^{ns}	APOE 2 or 4 genotype, n (%)	5 (27.8%) ^{ns}	1 (14.3%) ^{ns}	9 (56%) ^{ns}	
Median CDR-SOB (range) 5 (0 – 15) 0 (0 – 0) 1 (0 – 12)	Median CDR-SOB (range)	5 (0 - 15)	0 (0 – 0)	1 (0 - 12)	
0, n (%) 5 (28%) 7 (100%) 6 (37.5%)	0, n (%)	5 (28%)	7 (100%)	6 (37.5%)	
0.5, n (%) 1 (5.5%) 0 1 (6.3%)	0.5. n (%)	1 (5.5%)	0	1 (6.3%)	
1 p (%) 2(11%) 0 3(18.7%)	1. n (%)	2 (11%)	0	3 (18.7%)	
2, p(%) $0(0%)$ 0	2, n(%)	0 (0%)	0	0 (0%)	
>3. n (%) 10 (55.5%) 0 6 (37.5%)	>3. n (%)	10 (55.5%)	0	6 (37.5%)	
Median FTDRS RCVA (range)	Median ETDRS BCVA (range)	(
Right Eva letters $79(55-90)$ $90(83-90)$ $79(17-90)$	Right Eve letters	79 (55 - 90)	90(83 - 90)	79(17 - 90)	
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Left Eve letters	82(62 - 90)	30(03-30) 89.5 (89 - 90)	85(70 - 90)	
Interference O2 (02 30) O3 (03 30) O3 (70 30)	Median IOR (range)	82 (62 50)	89.9 (89 90)		
$\begin{array}{c} \text{Median IOP (range)} \\ \text{Dichet Exa} \\ 12 (9, 20)^{15} \\ 10 (10, 12)^{15} \\ 11 (9, 14)^{15} \\ $	Dight Evo	12 (8 20) ^{ns}	10 (10 12) 15	11 (9 14) ^{ns}	
Kigni Eye 12 $(\delta - 20)$ 10 $(10 - 13)$ 11 $(\delta - 14)$ L α F 40 $(2 - 10)^{15}$ 14 $(4 - 13)^{15}$ 14 $(4 - 13)^{15}$	Right Eye	12(8-20)	10(10-13)	11(8-14)	
Left Eye 10.5 (8 - 18) 11 (10 - 14) 11 (8 - 13)	Left Eye	10.5 (8 - 18)	11 (10 - 14)	11 (8 - 13)	
Median axial length (range)	Median axial length (range)				
Right Eye 22.9 (21.6 - 24.3)" 23.3 (22.9 - 26.5)" 23.52 (22.1 - 29)"	Right Lye	$22.9(21.6 - 24.3)^{10}$	$23.3(22.9 - 26.5)^{10}$	$23.52(22.1-29)^{10}$	
Left Eye 22.9 (21.3 – 24.5) ¹⁰ 23.3 (22.8 – 26.4) ¹⁰ 23.43 (22.0 – 29.3) ¹⁰	Left Eye	22.9(21.3 – 24.5)	23.3 (22.8 – 26.4)	23.43 (22.0 – 29.3)	
Median±lQR # retinal lesions, n (range) 11±13*, 348 (0–97) 7±7*, 38 (1 – 10) 4±8.5, 185 (0–64)	Median±lQR # retinal lesions, n (range)	11±13*, 348 (0–97)	7±7*, 38 (1 – 10)	4±8.5 , 185 (0-64)	
Superotemporal 4, 115 (0 - 26) 2, 18 (0 - 5) 2, 72 (0 - 35)	Superotempora	4, 115 (0 - 26)	2, 18 (0 - 5)	2, 72 (0 – 35)	
Superonasal 1, 32 (0 - 8) 0, 7 (0 - 5) 0.5, 41 (0 - 19)	Superonasa	1, 32 (0 - 8)	0, 7 (0 - 5)	0.5, 41 (0 - 19)	
Inferotemporal 2, 98 (0 – 26) 0, 10 (0 – 5) 1, 46 (0 – 23)	Inferotemporal	2, 98 (0 - 26)	0, 10 (0 - 5)	1, 46 (0 - 23)	
Inferonasal 1, 103 (0 – 76) 0, 3 (0 – 2) 1, 26 (0 – 10)	Inferonasa	1, 103 (0 - 76)	0, 3 (0 - 2)	1, 26 (0 - 10)	
Size of retinal lesions	Size of retinal lesions				
1 – 30 microns 310 (89.1%) 35 (92%) 148 (80%)	1 – 30 microns	310 (89.1%)	35 (92%)	148 (80%)	
3 0 – 60 3 0 (8.6%) 3 (8%) 2 3 (12.4%)	30 - 60	30 (8.6%)	3 (8%)	23 (12.4%)	
60 – 90 4 (1.1%) 0 7 (3.8%)	60 - 90	4 (1.1%)	0	7 (3.8%)	
90 – 120 3 (0.9%) 0 1 (0.5%)	90 – 120	3 (0.9%)	0	1 (0.5%)	
120 – 150 0 0 0	120 – 150	0	0	0	
150 – 180 0 2 (1.1%)	150 – 180	0	0	2 (1.1%)	
	180 – 210	0	0	0	
210 - 240 0 2 (1.1%)	210 - 240	0	0	2 (1.1%)	
240 - 270 1 (0.3%) 0 2 (1.1%)	240 270	1		· - · - · · /	
#>10 retinal lesions 10 ^{\$} (55.6%) 0 ^{\$} (0%) 4 ^{\$} (25%)	240-270	1 (0.3%)	0	2 (1.1%)	

Abbreviations: Autosomal Dominant Alzheimer's Disease (ADAD), Mild Cognitive Impairment (MCI), Clinical Dementia Rating Sum of Boxes Score (CDR-SOB), Early Treatment of Diabetic Retinopathy Score (ETDRS), BCVA (Best Corrected Visual Acuity), Intraocular Pressure (IOP), Interquartile Range (IQR) Footnotes:

(1) For subjects at risk for ADAD, age of disease onset differs more between mutations than within a mutation, so a mutation-specific adjusted-age of diagnosis can be calculated as an estimation of the time remaining from the expected age at which symptoms will develop. (2) Other diagnoses of systemic disease for Cohort 1 include: Cancer, Arthritis, B12 Deficiency, Incontinence, Sleep apnea, REM Sleep Behavior Disorder, Hyposomnia/insomnia, Depression, and Anxiety. (3) Other diagnoses of systemic disease for Cohort 2 include: Cancer, Arthritis, B12 Deficiency Incontinence, REM Sleep Behavior Disorder, Hyposomnia/insomnia, Depression, and Anxiety. (4) Other diagnoses of systemic disease for Cohort 3 include: Cancer, B12 Deficiency, Thyroid disease, Arthritis, Incontinence, Sleep apnea, REM Sleep Behavior Disorder, Hyposomnia/insomnia, Depression, and Anxiety. (4) Other diagnoses of systemic disease for Cohort 3 include: Cancer, B12 Deficiency, Thyroid disease, Arthritis, Incontinence, Sleep apnea, REM Sleep Behavior Disorder, Hyposomnia/insomnia, Cerebrovascular disease, Depression, and Anxiety. (NS) P < 0.05 Chi-squared test comparing: gender between cohorts, APOE 2 or 4 genotype between cohorts, and ANOVA comparing IOP and axial length between cohorts. (**) P = 5.181e-08 for ANOVA test comparing mean ages between Cohorts 1, 2, and 3. (*) P < 0.05 for Kolmogorov-Smirnov test comparing distributions of Cohort 1 vs. Cohort 2 or 3. (*) P < 0.05 for Chi-squared test comparing proportions of those with >10 retinal lesions. (*) one subject from cohort 2 and six subjects from cohort 1 did not have axial length data available. Numbers in bold indicated statistically significant differences.

Table 2. Retinal Thickness for Index Subject with PSEN1 Mutation Compared to Other Similar Reported Mutations and Controls From Literature				
Total Retinal Thickness (microns)				
Index Subject OD Average	324			
Index Subject OS Average	331			
PSEN1E280A Non-carriers ³⁰	344 <u>+</u> 16			
PSEN1E280A Carriers ³⁰	330 <u>+</u> 16			
Adhikari et al., ²²	337 <u>±</u> 13			
RNFL (microns)				
Index Subject OD Average	21			
Index Subject OS Average	25			
PSEN1E280A Non-carriers ³⁰	23 <u>+</u> 4			
PSEN1E280A Carriers ³⁰	23 <u>+</u> 4			
Adhikari et al., ²²	27 <u>±</u> 2			
GCL (microns)				
Index Subject OD Average	42			
Index Subject OS Average	44			
PSEN1E280A Non-carriers ³⁰	52 <u>+</u> 6			
PSEN1E280A Carriers ³⁰	51 <u>+</u> 8			
Adhikari et al., ²²	46 <u>±</u> 5			
IPL (microns)				
Index Subject OD Average	37			
Index Subject OS Average	37			
PSEN1E280A Non-carriers ³⁰	41 <u>+</u> 3			
PSEN1E280A Carriers 30	42 <u>+</u> 4			
Adhikari et al.,**	40 <u>+</u> 4			
ONL (microns)				
Index Subject OD Average	66			
Index Subject OS Average	61			
PSEN1E280A Non-carriers ³⁰	75±12			
PSEN1E280A Carriers ³⁰	67 <u>+</u> 9			
Adhikari et al., ²²	87 <u>±</u> 8			
Retinal thickness values for index subject and comparator values. Total ret	inal thickness and			
sublayer thickness values for index subject's left and right eyes were obtain	ed from the average			
of the central subfield and surrounding subfields with the 3mm ETDRS grid using commercially				
available segmentation software (Heidelberg Spectralis). Comparator average values from recent				
publications are listed for both eyes of subjects carrying known ADAD causing mutations or				
controls. RNFL = Retinal Nerve Fiber Layer. GCL = Ganglion Cell Layer				



Figure 2



Figure 3







12F4 (Aβ₄₂) GFAP CollV DAPI





11A50-B10 (Aβ40) IBA1 CollV DAPI



Figure 6

